Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns

Abstract

In this case-control study of 328 individuals exposed to anti-ERBB2 agents during pregnancy, exposure was associated with a severe specific adverse pregnancy and fetal or newborn outcomes compared with exposure to other anticancer treatments.